SCHEMBL25201563

SCHEMBL25201563

CCn1nnc2ccc(-c3c[nH]c4nc(NCC5CCN(C)CC5)ncc34)cc21

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 13/20 0.45
▸ DYRK1A Q13627 2/20 0.42
▸ CLK2 P49760 1/20 0.42
▸ CLK3 P49761 1/20 0.42
▸ DYRK1B Q9Y463 1/20 0.38
▸ SCN5A Q14524 1/20 0.37
▸ SCN9A Q15858 1/20 0.37
▸ CDK9 P50750 1/20 0.37
▸ BRD4 O60885 2/20 0.37
▸ VNN1 O95497 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30348319 1.00 TDO2 (0.45) TDO2DYRK1ACLK2CLK3DYRK1B
SCHEMBL25194734 0.91 DYRK1A (0.43) TDO2DYRK1ACLK2CLK3DYRK1B
SCHEMBL30346583 0.91 DYRK1A (0.43) TDO2DYRK1ACLK2CLK3DYRK1B
SCHEMBL30348149 0.88 TDO2 (0.44) TDO2DYRK1ACLK2CLK3CDK9
SCHEMBL25208447 0.88 TDO2 (0.44) TDO2DYRK1ACLK2CLK3CDK9
SCHEMBL25197263 0.88 DYRK1A (0.46) TDO2DYRK1ACLK2CLK3DYRK1B
SCHEMBL30348658 0.88 DYRK1A (0.46) TDO2DYRK1ACLK2CLK3DYRK1B
SCHEMBL30346989 0.85 TDO2 (0.45) TDO2DYRK1ACLK2CLK3BRD4
SCHEMBL25224210 0.85 TDO2 (0.45) TDO2DYRK1ACLK2CLK3BRD4
SCHEMBL30406857 0.84 DYRK1A (0.49) DYRK1ACLK2CLK3DYRK1BCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 — — US claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 TDO2 539/4885DYRK1A 1/4885CLK2 466/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 TDO2 539/4885DYRK1A 1/4885CLK2 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback